HC Wainwright Has Pessimistic Outlook of NTLA Q1 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – HC Wainwright reduced their Q1 2026 earnings estimates for shares of Intellia Therapeutics in a research report issued to clients and investors on Monday, March 2nd. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($0.97) for the quarter, down from their previous forecast of ($0.93). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. HC Wainwright also issued estimates for Intellia Therapeutics’ Q2 2026 earnings at ($0.88) EPS, Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($0.91) EPS and FY2026 earnings at ($3.71) EPS.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.16. The firm had revenue of $23.02 million during the quarter, compared to analyst estimates of $12.17 million. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.Intellia Therapeutics’s revenue was up 78.4% on a year-over-year basis. During the same period in the prior year, the business posted ($1.27) EPS.

Other research analysts also recently issued reports about the company. Leerink Partners boosted their price objective on Intellia Therapeutics from $27.00 to $29.00 and gave the company an “outperform” rating in a research note on Tuesday. Chardan Capital reaffirmed a “buy” rating and set a $26.00 price target on shares of Intellia Therapeutics in a report on Friday, February 27th. Robert W. Baird set a $7.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, January 27th. Canaccord Genuity Group reduced their price objective on shares of Intellia Therapeutics from $54.00 to $48.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Evercore set a $8.00 price objective on shares of Intellia Therapeutics and gave the company an “in-line” rating in a research report on Tuesday, November 11th. Ten research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $19.14.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $13.60 on Wednesday. The stock has a 50-day simple moving average of $12.09 and a two-hundred day simple moving average of $13.10. The firm has a market capitalization of $1.61 billion, a PE ratio of -3.55 and a beta of 2.10. Intellia Therapeutics has a 52-week low of $5.90 and a 52-week high of $28.25.

Institutional Investors Weigh In On Intellia Therapeutics

Several large investors have recently added to or reduced their stakes in NTLA. Oppenheimer & Co. Inc. raised its position in Intellia Therapeutics by 0.8% in the 4th quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock worth $945,000 after purchasing an additional 808 shares during the period. CWM LLC grew its stake in shares of Intellia Therapeutics by 4.7% during the third quarter. CWM LLC now owns 19,187 shares of the company’s stock valued at $331,000 after buying an additional 856 shares during the last quarter. Comerica Bank raised its holdings in shares of Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after buying an additional 901 shares during the period. Federated Hermes Inc. raised its holdings in shares of Intellia Therapeutics by 39.7% in the third quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock worth $56,000 after buying an additional 927 shares during the period. Finally, Cyndeo Wealth Partners LLC lifted its stake in shares of Intellia Therapeutics by 9.3% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 11,710 shares of the company’s stock worth $202,000 after acquiring an additional 995 shares during the last quarter. 88.77% of the stock is owned by institutional investors.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 34,146 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $314,484.66. Following the completion of the transaction, the chief executive officer owned 1,013,339 shares of the company’s stock, valued at $9,332,852.19. This represents a 3.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Birgit C. Schultes sold 8,508 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $78,358.68. Following the transaction, the executive vice president owned 98,533 shares of the company’s stock, valued at approximately $907,488.93. The trade was a 7.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 53,051 shares of company stock valued at $488,600. Corporate insiders own 3.10% of the company’s stock.

Intellia Therapeutics News Summary

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA removed the clinical hold on Intellia’s MAGNITUDE Phase 3 / heart‑disease gene therapy program — a major regulatory clearing event that had already pushed the stock higher. US FDA lifts clinical hold on Intellia’s heart disease gene therapy trial
• Positive Sentiment: Several brokers raised ratings/price targets (William Blair upgraded to Outperform; HC Wainwright, Citizens JMP and Leerink raised price targets), signaling improving analyst sentiment and potential re‑rating upside. Intellia Therapeutics (NASDAQ:NTLA) Upgraded by William Blair to “Outperform” Rating Analyst price target changes
• Positive Sentiment: Notable institutional/big‑name interest: Cathie Wood’s ARK (coverage article) is buying depressed growth names, which can attract investor attention and flows into beaten‑down biotech names. Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
• Neutral Sentiment: Company presented longer‑term clinical data for lonvo‑z at AAAAI (three‑year follow‑up and patient‑focused research) — supportive but not an immediate regulatory catalyst. Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z)
• Neutral Sentiment: Smaller price‑target increases from RBC and Wells Fargo to $15 provide modest near‑term support but signal only limited upside vs. some higher analyst targets. RBC & Wells Fargo PT raises
• Negative Sentiment: Canaccord trimmed its price target from $54 to $48 (still a Buy) — a reduction in optimism that could weigh on sentiment given prior higher targets and the stock’s recent run. Canaccord lowers price target

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.